|

BNT113 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2/3: 1

Top Sponsors

  • BioNTech SE1

Indications

  • Metastatic Head and Neck Cancer1
  • Recurrent Head and Neck Cancer1
  • Unresectable Head and Neck Squamous Cell Carcinoma1
  • Cancer1

Los Angeles, California1 trial

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1

California Research Institute

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.